Nanostructured Lipid Carriers: A Novel Generation of Solid Lipid Drug Carriers

Nanostructured lipid carriers are a new type of delivery system offering improved performance in terms of drug loading and long-term stability with the ability to form highly concentrated dispersions...

Articles in this issue

---

Nanotechnology Applications for Drug Delivery

Nanotech Not Big Enough for Pharma?

Protecting Intellectual Property Prior to Commercialization

Nanostructured Lipid Carriers: A Novel Generation of Solid Lipid Drug Carriers

Ion Exchange Resinates — The Technology Behind the Mystery

Maintaining the Safety of EU Drugs

Defining The Borders

The Effect of Core Design and Formulation on the Quality of Film Coated Tablets

Related Videos

Related Content

Advertisement

August 2nd 2025

Trump Sends Letters to 17 Leading Pharma Companies Outlining Most-Favored-Nation Drug Pricing Protocol

Patrick Lavery

If action is not taken within 60 days, the White House said it would “deploy every tool in our arsenal” to improve drug pricing practices for American patients.

August 2nd 2025

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

August 2nd 2025

In-line UV Spectrometry Monitoring in Cleaning Validation

John Schallom Brian Bosso Paul Lopolito Katie Frey Amy Thanavaro

The authors performed interference and enhancement testing using a formulated alkaline and acid cleaner, as well as common biopharmaceutical process residues.

August 2nd 2025

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.

August 2nd 2025

EMA Encourages Use of New Approach Methodologies to Reduce Animal Testing

Cheryl Barton

EMA is phasing out animal testing and is asking pharmaceutical companies to use new approach methodologies.

August 2nd 2025

GSK and Hengrui Pharma Collaborate on Drug Development

Susan Haigney

The two companies have entered into an agreement to develop respiratory, immunology, inflammation, and cancer therapies.

Related Content

Advertisement

August 2nd 2025

Trump Sends Letters to 17 Leading Pharma Companies Outlining Most-Favored-Nation Drug Pricing Protocol

Patrick Lavery

If action is not taken within 60 days, the White House said it would “deploy every tool in our arsenal” to improve drug pricing practices for American patients.

August 2nd 2025

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

August 2nd 2025

In-line UV Spectrometry Monitoring in Cleaning Validation

John Schallom Brian Bosso Paul Lopolito Katie Frey Amy Thanavaro

The authors performed interference and enhancement testing using a formulated alkaline and acid cleaner, as well as common biopharmaceutical process residues.

August 2nd 2025

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.

August 2nd 2025

EMA Encourages Use of New Approach Methodologies to Reduce Animal Testing

Cheryl Barton

EMA is phasing out animal testing and is asking pharmaceutical companies to use new approach methodologies.

August 2nd 2025

GSK and Hengrui Pharma Collaborate on Drug Development

Susan Haigney

The two companies have entered into an agreement to develop respiratory, immunology, inflammation, and cancer therapies.